SBD121, a Synbiotic Medical Food for RA Management

Rheumatoid Arthritis Clinical Trial

Official title:

A Randomised, Double Blind Placebo-controlled Trial Evaluating the Medical Food Synbiotic SBD121, Versus Placebo for the Clinical Dietary Management of Early Rheumatoid Arthritis.

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06005220
• Other study ID #: SOL-SYNBIOTIC-2023
• Status: Recruiting
• Phase: N/A
• Start date: September 30, 2023
• Est. completion date: September 2024

Study information

• Verified date: March 2024
• Source: Solarea Bio, Inc
• Contact: Eric Schott
• Phone: 585-704-8069
• Email: eschott[@]solareabio.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The aim of this randomised, double-blind, placebo controlled clinical food trial is to determine if the medical food SBD121 Synbiotic (prebiotic and probiotic) will aid in the dietary management of symptoms of early rheumatoid arthritis (RA).

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 140
• Est. completion date: September 2024
• Est. primary completion date: September 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Willing and able to provide written informed consent prior to the performance of any study-specific procedure and willing to comply with the protocol and report on compliance and side effects during study period.

2. Male or female aged 18 - 75 years inclusive at the time of consent.

3. The participant must have newly diagnosed RA, not exceeding 1-year from diagnosis

4. The participant must have been taking methotrexate (MTX) for treatment of RA for = 75 days before baseline, or will be commencing MTX at the same time as baseline (within range 15 to 25 mg inclusive, recommended target dose of 20mg).

5. The participant must have active RA meeting classification criteria according to the 2010 ACR/EULAR guidelines with a score equal to or greater than 6/10 at screening (11). (Seropositivity is not required).

6. The participant must be available throughout entire study period, willing and able to attend all scheduled visits and in the opinion of the Investigator be able to understand and comply with planned study procedures.

7. Body Mass Index (BMI) between 18.5 and 40 kg/m2

8. Normal cardiovascular parameters (systolic blood pressure = 150 mm Hg, diastolic blood pressure = 90 mm Hg). One re-test is permitted.

9. Women of childbearing potential must have a negative serum pregnancy test at screening and negative urine pregnancy test pre-first administration, on Day 1, and must agree to remain sexually abstinent, or use medically effective contraception (refer to Appendix 11.1), or have a partner who is sterile or same-sex, from Screening until end of study. Males must not be planning to father children or donate sperm for the duration of the study.

Exclusion Criteria:

1. Participant is currently taking any probiotic or prebiotic supplements, or has taken them in the past 7 days, or is unwilling to avoid taking probiotic/prebiotic supplements for the duration of the study.

2. Participant has any known or suspected allergies to probiotics or prebiotics.

3. Participant has taken oral or parenteral antibiotics within 21 days of screening, requires antibiotics pre-first dose, or is likely to require antibiotics during the study period.

4. Participant has undergone major surgery within last 3-months before screening or planned during the study period

5. Participant is a current smoker and/or uses nicotine replacement therapies (including vaping).

6. Participant has a past or current history of drug and/or alcohol abuse at the time of enrolment (the use of illegal drugs or the use of prescription or over-the-counter drugs or alcohol for purposes other than those for which they are meant to be used, or in excessive amounts).

7. Participant has a known history of any of the following (according to Investigator

judgement and/or participant report):

1. Gastric or intestinal dysmotility, slowed transit time, pancreatitis, or inflammatory bowel disease

2. Known Hepatitis B or Hepatitis C infection, cirrhosis or chronic liver disease

3. Underlying structural heart disease or previous history of endocarditis or valve replacement

4. Rheumatic disease other than rheumatoid arthritis, including but not limited to psoriasis, spondyloarthritis, systemic lupus erythematosus, multiple sclerosis

5. Immunosuppressed, including: known HIV positive; solid organ or stem cell transplant recipient; taking any oral or parenteral immunosuppressive therapy; neutrophil count <500/mm3; or anticipated drop in the neutrophil count to <500/mm3

6. Any malignancy, with the exception of non-melanoma skin cancers, or other cancer more than 5-years ago

7. Active tuberculosis (TB) within 3-months prior to Screening

8. Any infection requiring hospitalisation, or as otherwise judged clinically significant, within 3-months prior to Screening

8. Presence of any of the following active conditions at Screening, or within 72 hours of

the first administration of study test article:

1. Clinically significant abnormal vital signs or physical examination abnormalities (other than those related to RA, such as joint swelling)

2. Febrile illness (temp. > 37.5 degrees Celsius), or one or more episodes of diarrhoea within 72 hours of the first dose of study test article

3. Acute abdomen, colitis, or active GI disease

4. Septicaemia or bacteraemia

5. Uncontrolled diabetes mellitus, based on medical history and in response to query 'is your diabetes under control?'.

9. Current treatment with any Disease Modifying Arthritis Drug (DMARD) other than methotrexate including but not limited to, hydroxychloroquine, sulfasalazine, and minocycline leflunomide, gold compounds, azathioprine, or cyclosporine will be exclusionary if used within 30 days prior to randomisation.

10. Current or past treatment with any biologic agent including but not limited to tumor necrosis factor (TNF) inhibitors: etanercept, infliximab, adalimumab; interleukin 1 (IL-1) inhibitors: anakinra; lymphocyte directed: abatacept, rituximab; Janus kinase (JAK) inhibitors: tofacitinib; interleukin 17 (IL-17) inhibitors; Interleukin 23 (IL-23) inhibitors.

11. Corticosteroid use from 30 days prior to randomisation until final assessment visit

will be exclusionary, with the following exceptions:

1. Oral corticosteroids in low doses (= 10 mg/d prednisone or equivalent) will be allowed if stable for 1-month prior to randomisation. Reduction of dose or use of oral corticosteroids is permissible throughout the study.

2. Topical, inhaled, or intranasal steroids are permitted

3. Past use of oral or parenteral (> 10 mg/d prednisone or equivalent) corticosteroids is allowed if not used within 1-month prior to randomisation.

12. Women only - pregnant, planning on becoming pregnant during the trial, breastfeeding, positive urine pregnancy test during Screening or within 24 hours of first administration of study test article.

13. Any of the following abnormal findings on Screening or Baseline laboratory tests (one

re-test per timepoint permitted):

1. White blood cells (WBCs) < lower limit of normal (LLN) or > upper limit of normal (ULN). If WBC is documented within normal range prior to commencing steroids and is deemed by the Investigator as elevated at screening due to recent addition of these drugs and not related to any other comorbidities, then may be suitable to proceed.

2. Neutrophils < 1500/µl (1.5 x109/L)

3. Platelets < 100 x 10³/µl (100 x 109/L)

4. Haemoglobin < 9.0 g/dl (90 g/L)

5. Serum Creatinine > 1.5 x ULN

6. Glomerular filtration rate (GFR) of < or = 40 mL/minute

7. Aspartate aminotransferase (AST) > 3 x ULN

8. Alanine aminotransferase (ALT) > 3 x ULN

9. Total Bilirubin > 1.5 x ULN

14. Any other condition that in the opinion of the investigator would jeopardize the safety or rights of the volunteer participating in the study or would make it unlikely the volunteer could complete the study

15. If the participant has been in a recent experimental trial, these must have been completed not less than 60 days prior to this study.

Related Conditions & MeSH terms

• Arthritis
• Arthritis, Rheumatoid
• Rheumatoid Arthritis

Intervention

Other:
• SBD121
Medical Food
• Placebo
Placebo

Locations

Country	Name	City	State
Australia	Campbelltown Hospital	Campbelltown	New South Wales
Australia	Royal Prince Alfred Hospital	Camperdown	New South Wales
Australia	Paratus Clinical Canberra	Canberra	Australian Capital Territory
Australia	Liverpool Hospital	Liverpool	New South Wales
Australia	Linear Clinical Trials	Nedlands	Western Australia
Australia	Genesis Research Services	Newcastle	New South Wales
Australia	BJC Health	Parramatta	New South Wales
Australia	Western Health	St. Albans	Victoria
Australia	Latrobe Regional Hospital	Traralgon	Victoria
Australia	Westmead Hospital	Westmead	New South Wales
Australia	Princess Alexandra Hospital	Woolloongabba	Queensland
New Zealand	Aotearoa Clinical Trials	Auckland
New Zealand	Optimal Clinical Trials	Auckland
New Zealand	Southern Clinical Trials	Nelson

Sponsors (1)

Lead Sponsor	Collaborator
Solarea Bio, Inc

Countries where clinical trial is conducted

Australia,  New Zealand, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Microbiome functional composition by shotgun metagenomics	Change in the functional gut microbiota composition in stool samples from baseline and correlation with primary and secondary efficacy outcomes, at 16 weeks	16-weeks
Other	Microbiome taxonomic composition by shotgun metagenomics	Change in the taxonomic gut microbiota composition in stool samples from baseline and correlation with primary and secondary efficacy outcomes, at 16 weeks	16-weeks
Primary	American College of Rheumatology 20 (ACR-20)	Evaluate the dietary management of arthritis by the number and percentage of participants achieving American College of Rheumatology 20 (ACR20) response (ie, greater to or equal to 20% improvement in the ACR composite score, a measure of RA symptoms including: joint swelling and tenderness; patient's assessment of pain, arthritis activity, and physical function; physician's assessment of arthritis activity; and CRP) at Week 16	16 Weeks
Secondary	Safety by Adverse Events	Number and percentage of participants experiencing adverse events (AEs) and serious adverse events (SAEs)	16-weeks
Secondary	Tolerability by GITQ	Frequency and severity of GI symptoms (e.g., gas, abdominal pain, bloating) as assessed by the Gastrointestinal Tolerability Questionnaire (GITQ) score at each timepoint compared to placebo.	16-weeks
Secondary	American College of Rheumatology 20 (ACR-20)	Evaluate the dietary management of arthritis by the number and percentage of participants achieving American College of Rheumatology 20 (ACR20) response (ie, greater to or equal to 20% improvement in the ACR composite score, a measure of RA symptoms including: joint swelling and tenderness; patient's assessment of pain, arthritis activity, and physical function; physician's assessment of arthritis activity; and CRP) at Week 8	8 weeks
Secondary	American College of Rheumatology 50 (ACR-50)	Evaluate the dietary management of arthritis by the number and percentage of participants achieving ACR50 response in the ACR composite score at Week 8, and Week 16	8-weeks, 16-weeks
Secondary	American College of Rheumatology 70 (ACR-70)	Evaluate the dietary management of arthritis by the number and percentage of participants achieving ACR70 response in the ACR composite score at Week 8, and Week 16	8-weeks, 16-weeks
Secondary	Disease Activity Score 28 - Eosinophil Sedimentation Rate (DAS28 - ESR)	Evaluate the dietary management of arthritis by the percentage change from baseline value in the Activity Score-28 (DAS-28) with ESR (DAS-28-ESR), and the individual components that make up the DAS-28-ESR [Tender Joint Count (TJC), Swollen Joint Count (SJC), and Patients Global Assessment of Activity, plus Erythrocyte Sedimentation Rate (ESR)], at 8 and 16 weeks	8-weeks, 16-weeks
Secondary	Disease Activity Score 28 - C-Reactive Protein (DAS28 - CRP)	Evaluate the dietary management of arthritis by the percentage change from baseline value in the DAS-28 with CRP score and the individual components that make up the DAS-28 CRP Score [Tender Joint Count (TJC), Swollen Joint Count (SJC), and Patients Global Assessment of Activity, plus C-Reactive Protein (CRP)], at 8 and 16 weeks	8-weeks, 16-weeks
Secondary	Disease Activity Score 28 - Eosinophil Sedimentation Rate - Low Disease Activity (DAS28 - ESR - LDA)	Evaluate the dietary management of arthritis by the percentage of participants who achieve DAS-28-ESR Low Activity defined as DAS-28-ESR Score < 3.2, at 8 and 16 weeks	8-weeks, 16-weeks
Secondary	Disease Activity Score 28 - C-Reactive Protein - Low Disease Activity (DAS28 - CRP LDA)	Evaluate the dietary management of arthritis by the percentage of participants who achieve DAS-28-CRP Low Activity, defined as DAS-28-CRP Score < 3.2, at 8 and 16 weeks	8-weeks, 16-weeks
Secondary	Disease Activity Score 28 - Eosinophil Sedimentation Rate - Remission (DAS28 - ESR Remission)	Evaluate the dietary management of arthritis by the percentage of participants who achieve DAS-28-ESR Remission defined as DAS-28-ESR Score < 2.6, at 8 and 16 weeks	8-weeks, 16-weeks
Secondary	Disease Activity Score 28 - C-Reactive Protein - Remission (DAS28 - CRP Remission)	Evaluate the dietary management of arthritis by the percentage of participants who achieve DAS-28-CRP Remission, defined as DAS-28-CRP Score < 2.6, at 8 and 16 weeks	8-weeks, 16-weeks
Secondary	C-Reactive Protein (CRP)	Evaluate the dietary management of arthritis by the improvement in CRP from baseline	8-weeks, 16-weeks
Secondary	Eosinophil Sedimentation Rate (ESR)	Evaluate the dietary management of arthritis by the improvement in ESR from baseline	8-weeks, 16-weeks
Secondary	Zonulin	Evaluate improvement in gastrointestinal permeability by improvement in Zonulin from baseline	8-weeks, 16-weeks
Secondary	Reduce or discontinue use of oral corticosteroids	Evaluate the dietary management of arthritis by the number and percentage of participants able to reduce dose or discontinue use of oral corticosteroids, at 8 and 16 weeks	8-weeks, 16-weeks
Secondary	Reduce or discontinue use of oral NSAIDs	Evaluate the dietary management of arthritis by the number and percentage of participants able to reduce dose or discontinue use of oral NSAIDs, at 8 and 16 weeks	8-weeks, 16-weeks